<p>Volition Veterinary, a VolitionRX Subsidiary, to Eliminate CEO Position in Cost-Realignment Move Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-25-008932), on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

VNRX

<p>Volition Veterinary, a subsidiary of VolitionRX, is eliminating the CEO position as part of a cost realignment strategy. This decision was disclosed in a document published by VolitionRX Ltd. via the U.S. SEC's EDGAR system. The information is provided by Public Technologies using AI and is intended for informational purposes only.</p>

Volition Veterinary Eliminates CEO Role Amid Cost Realignment